Chairman and CEO
Reginald (Reg) Dupre
Mr. Reginald (Reg) Dupre has led EPIEN Medical since 1999 and steered it through its start-up and its technology development stages with strong leadership as CEO. During the past five years, Reg has led the company through its commercialization stage and today the company’s products are sold in more than 40 countries. Under Reg’s insightful leadership, the company’s vision to develop and implement a state-of-the-art nonbiologic technology platform has come to fruition. This novel platform technology transcends dental, acute and chronic wound, surgical, dermatological, veterinary and other medical specialties applications worldwide. He has also guided EPIEN’s marketing efforts to expand brand recognition of its oral healthcare products ORALMEDIC®, HYBENX® and soon REVITY™ at a global level.
As chairman and CEO of EPIEN Medical, Reg has arranged capital from angel investors to large institutional investments to pave the company’s path to becoming a global leader in advanced non-antibiotic therapies.
Prior to becoming CEO of EPIEN Medical, Reg held various board-elected leadership positions in several start-ups and mature companies that needed turnaround leadership expertise and/or needed $1M in new capital. Some of these companies include Sustane Corporation, Rem-Con and the Minnesota Renaissance Festival. Prior to these executive roles or capital raises, Reg spent 14 years in a variety of business development, strategic marketing, and sales management roles at Honeywell and Control Data.
Following Reg’s undergraduate work at the University of Minnesota, he received a bachelor’s degree in Business Administration from the Metropolitan State University. He continued his studies at the University of St. Thomas in International Marketing.